Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Natalie Galanina

    TitleAssistant Clinical Professor
    SchoolUniversity of California, San Diego
    Address9500 Gilman Drive #0987
    CA La Jolla 92093
    vCardDownload vCard

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Galanina N, Smith SM, Liao C, Petrich A, Libao B, Gartenhaus R, Westin JR, Cohen KS, Knost JA, Stadler WM, Doyle A, Karrison T, Gordon LI, Evens AM. University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. Br J Haematol. 2017 Apr 17. PMID: 28419407.
        View in: PubMed
      2. Galanina N, Kline J, Bishop MR. Emerging role of checkpoint blockade therapy in lymphoma. Ther Adv Hematol. 2017 Feb; 8(2):81-90. PMID: 28203344.
        View in: PubMed
      3. Galanina N, Jasielec J, Peace D, Smith SM, Nabhan C. Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2017 Mar; 58(3):752-753. PMID: 27415580.
        View in: PubMed
      4. Galanina N, Petrich A, Nabhan C. The evolving role of lenalidomide in non-Hodgkin lymphoma. Leuk Lymphoma. 2016 Jul; 57(7):1507-16. PMID: 26902680.
        View in: PubMed
      5. Guo A, Lu P, Galanina N, Nabhan C, Smith SM, Coleman M, Wang YL. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. Oncotarget. 2016 Jan 26; 7(4):4598-610. PMID: 26717038; PMCID: PMC4826229.